Newleos Therapeutics, a US neuroscience company with a focus on CNS drug development, has raised $93.5 million in an oversubscribed series A funding round.  The financing was led by Goldman Sachs Alternatives with participation from Novo Holdings A/S, Longwood Fund, DCVC Bio, and Arkin Bio Capital.

Newleos’ clinical-stage pipeline was in-licensed from Roche and includes multiple oral small molecules targeting novel mechanisms across a broad range of indications including generalised anxiety, social anxiety, substance use disorders and cognitive impairment.